Abstract
Acute GVHD (aGVHD) is a major cause of morbidity and mortality after unrelated BMT (UBMT). Our purpose was to analyze the role of extracorporeal photochemotherapy (ECP) in controlling grade II–IV aGVHD in children given UBMT. Of 41 consecutive children, 31 developed grade II–IV aGVHD after UBMT: 16 had a good response to steroids (GR group), whereas 15 underwent ECP (ECP group) within 100 days of UBMT. Eligibility criteria for starting ECP were steroid resistance, dependence or viral reactivations. Criteria for judging response to aGVHD treatment were that the resolution of all signs were considered a complete response (CR), at least a 50% improvement was classified as a partial response (PR) and stable or progressive disease was judged as no response (NR). On completing ECP, the CR rate was 73%, whereas the GR group had a CR rate of 56% by day 100. The 2-year overall survival and progression-free survival rates were 57 and 67% in the GR group vs 85 and 87% in the ECP group. Our data seem to suggest that ECP may improve outcome in patients after UBMT. These findings need to be confirmed in a larger population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.
Bacigalupo A . Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87–98.
Deeg HJ, Loughran Jr TP, Storb R, Kennedy MS, Sullivan KM, Doney K et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40: 162–166.
Pavletic S, Tarantolo S, Lynch J, Oria N, Ketcham M, Brand R et al. Acute graft-versus-host disease after allogeneic blood stem cell transplantation: factors determining treatment failure and survival. Blood 1999; 94 (Suppl 1): 153a.
Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118–127.
Peritt D . Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 7–12.
Ferrara JL, Deeg HJ . Graft-versus-host disease. N Engl J Med 1991; 324: 667–674.
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Deeg HJ, Storb R . Graft-versus-host disease: pathophysiological and clinical aspects. Annu Rev Med 1984; 35: 11–24.
Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006; 91: 405–408.
Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B et al. Extracorporeal photochemotherapy for treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074–3080.
Marubini E, Valsecchi MG . Analysing Survival Data from Clinical Trials and Observational Studies. Wiley: Chichester, 1995.
Acknowledgements
We gratefully acknowledge MC Putti for critically reviewing the article. We also thank I Taddeo, A Eccellente and S Gallo for their excellent secretarial assistance. CM is particularly grateful to Professor L Zanesco for his guidance and sage advice over the years. This work was supported by the Fondazione Città della Speranza and AIL (Associazione Italiana Leucemie e Linfomi).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calore, E., Calò, A., Tridello, G. et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 42, 421–425 (2008). https://doi.org/10.1038/bmt.2008.174
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.174
Keywords
This article is cited by
-
Shortened apheresis-based extra-corporeal photochemotherapy for acute refractory GVHD in children: a prospective study
Bone Marrow Transplantation (2016)
-
Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature
Bone Marrow Transplantation (2014)
-
Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies
Cancer Immunology, Immunotherapy (2014)
-
New developments in acute graft-versus-host disease
memo - Magazine of European Medical Oncology (2013)
-
Extracorporeal photochemotherapy as second- or first-line therapy of acute GVHD?
Bone Marrow Transplantation (2010)